Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue $ 687 $ 539
Costs of revenue 223 118
Gross profit 464 421
Operating expenses:    
Research and development 2,019 2,200
General and administrative 1,123 1,169
Sales and marketing 246 310
Grant expenses 273 299
Total operating expenses 3,661 3,978
Loss from operations (3,197) (3,557)
Other income (expenses):    
Interest expense (2) (2)
Interest income 19 38
Change in fair value of derivative liabilities 2,838 4,006
Offering costs of derivative liabilities (550) (786)
Other income (net) 6 8
Total other income, net 2,311 3,264
Net loss before income taxes (886) (293)
Provision for income taxes
Net loss $ (886) $ (293)
Net loss per share – basic and diluted    
Basic – net loss $ (0.05) $ (0.13)
Diluted – net loss $ (0.11) $ (1.74)
Weighted average common shares outstanding:    
Basic 17,262,895 2,272,992
Diluted 34,460,877 2,558,059
Product [Member]    
Total revenue $ 309 $ 240
Grant And Contract [Member]    
Total revenue $ 378 $ 299